Navicixizumab (OMP305B83)
For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.
Our partners have a mission-critical role to play – providing the resources, skills and perspective that is integral to the development of therapies.
"We seek to leverage the strong development and regulatory progress Mereo has already made to continue the development of navicixizumab and ultimately make this investigational therapy available to patients as quickly as possible.”
Laura E. Benjamin, Ph.D., Chief Executive Officer of OncXerna
Mereo BioPharma and Ultragenyx to Present Setrusumab Data Update at ASBMR
Mereo BioPharma and Ultragenyx Pharmaceutical Inc. today announced that additional data relevant to setrusumab will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR) being held September 9-12, 2022, in Austin, Texas.
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.
Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group presented secondary endpoint data on UX143 (setrusumab) from the Phase 2b ASTEROID study for the Treatment of Osteogenesis Imperfecta (OI). Data were presented at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Study to be Conducted at The University of Texas MD Anderson Cancer Center LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas , April 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer.
Mereo actively seeks partners with aligning strategic priorities and values to ensure that we can unlock the full potential of our pipeline for all stakeholders, particularly patients.
We currently have three clinical-stage programs with partnering opportunities.
For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
For the potential treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).
Mereo acquired a portfolio in July 2015 including Setrusumab, Acumapimod and Leflutrozole.
Mereo in-licensed Alvelestat from AstraZeneca In October 2017.
In December 2020, Mereo entered a collaboration and license for the development and co-commercialization of Setrusumab.
Mereo out-licensed Navicixizumab to OncXerna in January 2020.
Please do not send any confidential information using the form. We look forward to hearing from you.